Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatments after Prostate Surgery

22.01.2009
Although primary prostate surgery or radiotherapy is successful in many cases of prostate cancer, some patients will suffer a recurrence of the disease, which is most often first detected by a measurable PSA blood test.

This so-called biochemical recurrence affects 30% to 40% of patients after surgery. One risk factor for recurrence, the presence of cancer potentially outside the prostate after surgery, will affect about a third of men. Two studies in the March 2009 issue of The Journal of Urology report on clinical studies of treatment options.

Men who show increasing Prostate-Specific-Antigen (PSA) after surgery but without signs of metastases are offered a variety of options for treatment, including radiation, prostatectomy, observation or androgen deprivation therapy (ADT). Unfortunately virtually all patients treated with ADT progress to metastatic disease. Researchers investigated the addition of thalidomide to intermittent ADT in a double-blind, placebo-controlled multicenter study.

Intermittent ADT is increasingly being used in patients with biochemical recurrence since it has some advantages over continuous ADT. In this study, patients were first given ADT for 6 months, followed by thalidomide or placebo until their PSA increased (Oral Phase A) and the authors found that the median time to PSA increase was 15 months for the thalidomide patients versus 9.6 months for placebo. The next phase, Oral Phase B (OPB), was another 6 months of ADT followed by thalidomide and placebo, now switched between patient groups. During OPB, the median time to PSA increase was 17.1 months for thalidomide and 6.6 months for placebo.

Research conducted in 1994 found that thalidomide, an agent originally synthesized in 1954 and used as a sedative until it was linked to more than 10,000 severe malformations in infants, had antiangiogenic activity.

Writing in the article, William D. Figg, Medical Oncology Branch of the National Cancer Institute, National Institutes of Health, states, “Thalidomide is associated with an increase in PSA progression-free survival in men with biochemically recurrent prostate cancer after intermittent ADT. These effects were independent of any effects on testosterone. This is the first study to our knowledge to demonstrate the effects of thalidomide using intermittent hormonal therapy.”

Another multi-institution study, led by Ian M. Thompson, MD, University of Texas Health Science Center at San Antonio, demonstrates that adjuvant radiotherapy significantly improves survival after radical prostatectomy in patients with advanced prostate cancer. In this study initiated in 1988 of 425 men with aggressive prostate cancer, 211 were observed after surgery for signs of recurrence, and 214 received adjuvant radiotherapy shortly after surgery. Unlike most studies which have based results on PSA recurrence, this study’s endpoint was development of metastatic disease.

When data were most recently evaluated in 2008 after an average 12.7 year follow-up, radiation was found to significantly reduce the risk of metastases by 29% and significantly improved survival by 28%. In addition to the most important outcomes of prostate cancer (metastases and survival), the risk of a detectable PSA after surgery (the first evidence of disease recurrence) was reduced by 58% and delayed by more than 7 years. The authors found that all risk groups studied appeared to benefit.

Radiation therapy also significantly reduced the need for hormone therapy after surgery, a treatment which can have profound negative impacts on quality of life. Using measures of quality of life, the study found increases in patients’ urinary and bowel symptoms in the radiotherapy group at six weeks and two years, but these differences subsequently disappeared.

Dr. Thompson commented that “Adjuvant radiotherapy within 18 weeks after radical prostatectomy in a man with pT3N0M0 prostate cancer significantly reduces the risk of PSA recurrence, metastasis and the need for hormonal therapy, and significantly increases survival. All of the approximate 30,000 men each year that face this condition should be informed of the results of this study.”

Featured articles are “A Double Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo in Patients With Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation” by William D. Figg, Maha H.Hussain, James L. Gulley, Philip M. Arlen, Jeanny B. Aragon-Ching, Daniel P. Petrylak, Celestina S. Higano, Seth M. Steinberg, Gurkamal S. Chatta, Howard Parnes, John J. Wright, Oliver Sartor and William L. Dahut, and “Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial” by Ian M. Thompson, Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, Gary Miller, Dean Troyer, Edward Messing, Jeffrey Forman, Joseph Chin, Gregory Swanson, Edith Canby-Hagino and E. David Crawford.

Both appear in The Journal of Urology, Volume 181, Issue 3 (March 2009) published by Elsevier.

Linda Gruner | alfa
Further information:
http://www.elsevier.com

More articles from Health and Medicine:

nachricht Lung images of twins with asthma add to understanding of the disease
06.12.2019 | University of Western Ontario

nachricht Between Arousal and Inhibition
06.12.2019 | Albert-Ludwigs-Universität Freiburg im Breisgau

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Developing a digital twin

University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making

In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...

Im Focus: The coldest reaction

With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction

The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...

Im Focus: How do scars form? Fascia function as a repository of mobile scar tissue

Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.

Fibroblasts kit - ready to heal wounds

Im Focus: McMaster researcher warns plastic pollution in Great Lakes growing concern to ecosystem

Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.

In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...

Im Focus: Machine learning microscope adapts lighting to improve diagnosis

Prototype microscope teaches itself the best illumination settings for diagnosing malaria

Engineers at Duke University have developed a microscope that adapts its lighting angles, colors and patterns while teaching itself the optimal...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Solving the mystery of carbon on ocean floor

06.12.2019 | Earth Sciences

Chip-based optical sensor detects cancer biomarker in urine

06.12.2019 | Life Sciences

A platform for stable quantum computing, a playground for exotic physics

06.12.2019 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>